Leon L Su

US Patent:

20210269498, Sep 2, 2021

Filed:

May 13, 2021

Appl. No.:

17/320174

Inventors:

- Palo Alto CA, US
Sonia S. MAJRI - Palo Alto CA CA, US
Caleb R. GLASSMAN - Palo Alto CA, US
Leon Lih-Ren SU - Mountain View CA, US

International Classification:

C07K 14/55
A61P 37/00
C07K 16/24
C12N 15/63

Abstract:

Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2Rγ. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

US Patent:

20210238258, Aug 5, 2021

Filed:

Sep 10, 2020

Appl. No.:

17/017522

Inventors:

- Stanford CA, US
Leon Lih-Ren Su - Stanford CA, US

International Classification:

C07K 14/715
C07K 14/72
A61K 35/17

Abstract:

Engineered orthogonal chimeric receptor/ligand pairs, and methods of use thereof, are provided.

US Patent:

20200299349, Sep 24, 2020

Filed:

Nov 20, 2018

Appl. No.:

16/765617

Inventors:

- Palo Alto CA, US
Sonia S. MAJRI - Palo Alto CA, US
Caleb R. GLASSMAN - Palo Alto CA, US
Leon Lih-Ren SU - Mountain View CA, US

International Classification:

C07K 14/55
C12N 15/63
A61P 37/00
C07K 16/24

Abstract:

Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2Rγ. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.